Sentence examples for duration of boosting from inspiring English sources

However, we note that our parameter sets allow the "x" to be very large so that the duration of boosting could even go up to 20 years.

The exponential decay is defined by the peak and duration of boosting: Y (t ) = P ⋅ Y 0 ⋅ e − ln (P ) x ⋅ t with Y t) = VZV-CMI (disregarding age), P = peak fold increase, Y0 = VZV-CMI prior to entering boosting sequence (= 'original VZV-CMI') and x = duration of boosting.

The two best fitting parameter sets predicted peak boosting values between 2.8 and 4 (maximum allowable value), a duration of boosting limited to 1 or 2 years and, as before, no endogenous boosting.

Although our model predicts a much lower duration of boosting than used hitherto in compartmental models (Ogunjimi et al., 2013), some of our overall HZ projections are qualitatively similar.

This model allowed us to combine immunological and virological data to estimate key parameters in VZV population dynamics, such as the peak CMI response following re-exposure, duration of boosting and VZV subclinical reactivation characteristics.

Next, VZV-CMI will decrease following one of three different boosting scenarios (as shown in Figure 8) until it reaches the pre-boosting value again (after a 'duration of boosting'): Exponential decrease from peak to pre-boosting value based on VZV ELISPOT CMI data after Zostavax vaccination as published by Levin et al. (2008).

One of the main points of criticism on current predictions by deterministic VZV simulation models is the entanglement of exogenous boosting, waning of immunity, immunosenescence and reactivation undermining the possibility of estimating the magnitude and duration of exogenous boosting accurately.

We conclude that our VZV individual-based model has explicitly estimated the duration of exogenous boosting to be limited to only 1 or 2 years and that there was no significant effect from endogenous boosting.

Our best fitting parameter sets for Belgium suggest the effective duration of exogenous boosting to last only between 1 and 2 years.

This paper offers a number of improvements that may enhance the believability of conclusions, particularly an individual-based structure which allows tracking of within-host immune dynamics, allowing the duration of exogenous boosting to be fitted rather than largely assumed.

This model allows estimating currently unknown pivotal biomedical parameters, including the duration of exogenous boosting at 2 years, with a peak threefold to fourfold increase of VZV-CMI; the VZV weekly reactivation probability at 5% and VZV subclinical reactivation having no effect on VZV-CMI.